Introduction
Gene expression profiling in tumor samples is a powerful tool for understanding how genetic factors influence tumor morphology and progression [1] [2] [3] . However, profiling of primary melanomas is challenging, because primary melanoma tumors are relatively small, and, for lesions that are heavily or moderately pigmented, melanin can inhibit some downstream applications [4] . In addition, nucleic acids obtained from archived formalinfixed paraffin-embedded (FFPE) samples are usually fragmented and chemically modified by formaldehyde because of fixation and embedding conditions, and DNA or RNA from FFPE samples are often of a lower molecular weight than those obtained from fresh or frozen samples [5] . Because of these challenges, gene expression studies on primary melanomas are limited. Xu et al. [6] analyzed gene expression in 31 primary melanomas and identified a 150-gene signature associated with survival. Another study reported on a number of genes differentially expressed between 45 primary melanomas and 18 benign skin nevi [7] . Riker et al. [8] compared gene expression in 16 primary and 40 metastatic melanomas and identified genes associated with metastases. Several other studies focused on developing a prognostic signature on the basis of gene expression in primary tumors with a rather limited number of samples [7] [8] [9] [10] [11] [12] . Even though gene expression data generated by those studies are publicly available, the clinicopathologic characteristics of the primary melanomas are not described. Jönsson et al. [13] carried out unsupervised hierarchical clustering of global gene expression data from stage IV Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website, www.melanomaresearch.com. metastatic melanomas in 57 patients. The authors identified four melanoma subtypes characterized by expression of immune response, pigmentation differentiation, proliferation, or stromal composition genes. Those subtypes were later recapitulated in primary tumors [14, 15] . Jewel et al. [16] used a 502-gene cancer panel to identify genes associated with ulceration of primary melanomas.
The Cancer Genome Atlas (TCGA) comprises the largest series of melanomas, with 103 primary Skin Cutaneous Melanoma (SKCM) samples; however, gene expression data are available for only 43 of them. Despite the incomplete clinical annotation of SKCM, we used TCGA SKCM samples for in-silico validation of findings from discovery analyses performed on primary melanoma samples we collected.
The goals of this analysis were to identify genes whose expression level in primary melanomas correlates with clinically relevant characteristics and to validate the associations using TCGA data. This research represents a pilot phase of the InterMEL-consortium, which is seeking to identify biomarker signatures that predict recurrence from primary, early-stage cutaneous melanomas. The clinical characteristics examined included sex, presence of tumor-infiltrating lymphocytes (TILs) based on histologic analysis of primary melanoma, Breslow thickness, tumor mitotic rate (TMR), lymph node (LN) status, and ulceration, and were selected because of their association with clinical outcomes. Numerous studies, beginning over 50 years ago, have shown that melanoma mortality is higher in men than women [17] [18] [19] [20] . The presence of TILs within a melanoma can predict both survival and response to treatment in melanoma [21] . Breslow's thickness describes how deeply tumor cells have invaded the skin and is an important prognostic factor in melanoma survival [22] . TMR is defined as the number of mitoses/mm 2 and is a predictor of melanoma survival, with a higher TMR associated with poorer survival [23] . Melanoma involvement in at least one LN is an important predictor of survival and is also used in melanoma staging [24] . Finally, the 5-year survival rate is lower in ulcerated stage I and II melanomas, as compared with nonulcerated melanomas of the same stage [25] .
Patients and methods

Patient population
Tumors from two institutions were used with Institutional Review Board approval for exempt studies (exemption 4, no identifiers and patients deceased): Case Western Reserve University (n = 16) and the University of New Mexico (n = 18) provided the samples that were used in this study. Table 1 provides the clinical description of samples. Table 1 includes 32 samples after two samples were removed because of QC issues and low RNA concentration.
Clinical characteristics
We abstracted the following characteristics of tumors/ patients from medical records, including sex, TILs in primary melanoma, Breslow's thickness, TMR, LN status, and ulceration.
RNA extraction
Ten sections, 5 or 10 μm each, were obtained from archived FFPE tissue blocks, placed on uncharged glass slides, and shipped to the Molecular Epidemiology Laboratory at Memorial Sloan Kettering Cancer Center. Tissue sections were kept at 4°C while awaiting nucleic acid extraction. Hematoxylin-eosin-stained sections were evaluated by a dermatopathologist to confirm the presence of melanoma, determine the histologic features and tumor purity, and guide the macrodissection and microdissection. RNA and DNA were extracted with the ALLPrep DNA/RNA FFPE kit (Qiagen, Germantown, Maryland, USA) using the Qiagen deparaffinization solution and according to the manufacturer's recommendations. The RNA quantities and A 260 / A 280 and A 260 /A 230 ratios (to examine presence of proteins or organic solvents) were determined with a Nanodrop 8000 (Thermo Scientific, Waltham, Massachusetts, USA). The RNA quality was assessed with a TapeStation 2200 (Agilent, Lexington, Massachusetts, USA).
Selection of genes and assessment of gene expression
Tumor-derived RNA samples were profiled using NanoString nCounter custom codesets (NanoString Technologies, Seattle, Washington, USA). This involved the use of a digital color-coded barcode technology, which enabled us to measure the expression of a number of candidate genes with a high level of precision and sensitivity, and without the interference of melanin present in pigmented tumors. For this, a set of 760 genes were selected for inclusion in the gene expression analysis, on the basis of published evidence of their association with any aspect of melanoma initiation, progression, or response to treatment. Forty housekeeping genes were included as internal controls. The complete list of the gene used in this analysis can be found in Supplementary Table S1 (Supplemental digital content 1, http://links.lww.com/MR/A50).
Expression data normalization and robustness
For each sample, the geometric mean of each of the positive controls was calculated with the nSolver software analysis tool (NanoString Technologies, Seattle, Washington, USA) to estimate the overall assay efficiency. Using nSolver software, raw data were first normalized using the average of the geometric means of six expression sequences not present in any known organism, which were spiked into the samples and served as positive controls. Counts were normalized for all target RNAs in all samples on the basis of the positive control RNA, to account for differences in hybridization efficiency and posthybridization processing, including purification and immobilization of complexes (one sample outside the range of 0.3-3 was removed). Housekeeping genes were then removed if the mean intensity was less than 2 SDs above the mean of the negative controls (six random sequences not present in any organism and not spiked into the samples) or if the coefficient of variation of the intensity of each housekeeping gene divided by the geometric mean of all housekeeping genes for each sample was greater than 90% (geNorm algorithm [26] ). Subsequently, the mRNA content normalization was performed using the average of the geometric means of the acceptable housekeeping genes as a scaling factor for the endogenous targets. There were no samples with scaling factors outside the range of 0.10-10.
TCGA samples
Clinical and gene expression data were downloaded from the TCGA data portal. Gene expression data in the TCGA were available for 43 primary melanoma samples. A total of 753 of the original 760 genes assessed in the pilot InterMEL study were also reported in TCGA. None of these genes were nominally significantly associated with any clinical features studied in the discovery analysis.
Survival analysis
Patients were treated by standard therapy including surgery and chemotherapy or radiation therapy. We used Kaplan-Meier analysis (log-rank test) to compare subjects with high (≥ median) versus low (< median) level of expression by overall survival. Each gene was analyzed separately.
To test the relevance of the results of the analysis of primary melanomas to metastatic melanomas, we identified differentially expressed genes between LN-positive versus LN-negative primary tumors. A total of 14 genes that were significant in both InterMEL and TCGA samples have been analyzed: PIK3CG, PLCG2, TLR4, CASP8, ITGA8, IL2RB, FLT1, RAC2, NTRK1, IL2RA, IL7R, JAK2, RASGRP1, and HSP90B1. All these genes were downregulated in LN-positive samples. The logarithm of the average expression across the genes was used as a score to predict survival. The median score was used to stratify cases into high or low average expression. Metastatic (total 460) TCGA samples and metastatic (total 214) samples from the GEO GSE65904 data set [27] were used in the analysis. In GSE65904, gene expression was measured by the Illumina HumanHT-12 microarray platform (48 107 probes, Illumina, San Diego, California, USA). Probe expressions were converted into gene expressions by choosing the probe with the largest average expression across all samples.
Statistical analysis
Our hypothesis was that gene expression in primary melanomas is associated with clinically relevant tumor and/or patient characteristics. In univariate analyses, we used nonparametric correlation to detect associations of clinically relevant characteristics with TILs, Breslow's thickness, and TMR. Associations of the gene expression level with binary characteristics (sex, LN status, and ulceration status) were assessed using t-statistics. The Benjamini-Hochberg false discovery rate (FDR) method was used to adjust for multiple testing [28] . We separated our samples into a discovery sample, using primary data from the pilot InterMEL samples, and a validation sample, using an in-silico analysis of SKCM TCGA sample expression and clinical data. Associations nominally significant in the discovery analysis were used in the validation analysis. Statistical significance in the validation analysis was decided on the basis of the number of tests in the validation phase. We then performed a combined analysis of both samples by using inverse variance metaanalysis of pilot InterMEL and TCGA results.
For multivariate analysis, we have used least absolute shrinkage and selection operator (LASSO) implemented in Statistica (StatSoft, Boston, Massachusetts, USA). Logistic (for binary outcome) or linear (for continuous outcome) regressions were used. Tuning parameter λ was selected to make the number of non-zero β-coefficients not exceeding the number of predictors in univariate analysis with liberal FDR of less than 0.2.
We used gene set enrichment analysis (GSEA) [29] to identity biological functions enriched by the genes upregulated or downregulated in the given phenotypedifferentially expressed genes. We used curated hallmark GSEA gene sets. Gene sets with FDR of less than 0.05 were considered to be significant.
Results
Univariate analysis
Of the 34 tested InterMEL-pilot RNA samples, one failed QC, and one had insufficient RNA, resulting in 32 evaluable samples used in this study.
Genes differentially expressed by sex
We identified 30 genes differentially expressed between male and female patients. The list of the genes with the corresponding P values for sex difference can be found in Supplementary Table S2 (Supplemental digital content 2, http://links.lww.com/MR/A51). For two genes, KDM5C and KDM6A, the expression was much higher in female patients compared with male patients. The differences for these two genes remained significant after the adjustment for multiple testing: P =0.01 and 0.02, correspondingly. Those are the only genes that were reproduced by the analysis of TCGA data. Figure 1a shows the heat map of the genes nominally associated with sex.
Genes associated with tumor-infiltrating lymphocytes
TILs were coded as '0', '1', and '2' for absent, nonbrisk, and brisk TILs, correspondingly. For each gene, we calculated Spearman's correlation coefficient between the gene expression and TILs. We identified 110 genes nominally associated with TILs (Supplementary Table S3 , Supplemental digital content 3, http://links.lww.com/MR/A52).
None of these associations remained statistically significant after adjustment for multiple testing. Twenty-four of the nominally significant genes identified in the InterMEL-pilot were also significantly associated with TILs in TCGA:  AQP3, CBLC, CEBPA, CRABP2, EGFR, ERBB2, FLT3,  IL1B, IL1R2, IL7R, ITGB4, JAG2, LAMA3, LAMB3, LAMC2,  PBX1, PLA2G3, PLA2G4F , PPL, PRDM1, RASAL1, SFN, SGK2, and WNT11. For the associations that were common to both data sets, the direction of the effect (positive or negative) was the same. In the joint analysis, five genes remained significant after the adjusting for multiple testing: IL1R2, PPL, PLA2G3, RASAL1, and SGK2. Figure 1b shows the heat map of the genes nominally associated with TIL status.
Lymph node status
We identified 131 genes associated with LN status coded as LN positive versus LN negative. The list of the genes can be found in Supplementary Table S4 (Supplemental digital content 4, http://links.lww.com/MR/A53). We found that 15 genes, PIK3CG, PLCG2, TLR4, CASP8, ITGA8, IL2RB, FLT1, RAC2, NTRK1, IL2RA, IL7R, ALKBH3, JAK2, RASGRP1, and HSP90B1, were also nominally significant in TCGA. PIK3CG expression remained statistically significant in the validation set after the adjustment for multiple testing, and IL2RA remained statistically significant in the joint analysis of the pilot and validation tests after the adjustment for multiple testing. Figure 1c shows the heat map of the genes nominally associated with LN status.
Ulceration
Thirty-one genes were detected as nominally statistically significant for an association of their expression with ulceration status, coded as present versus absent (Supplementary  Table S5 , Supplemental digital content 5, http://links.lww.com/ MR/A54 ). Only one gene, IL23A, was also nominally significant in TCGA (t = 2.4, P = 0.02). The association was not significant after the adjustment for multiple testing. Figure 1d shows the heat map of the genes nominally associated with ulceration status.
Breslow thickness
We identified 69 nominally significant genes (Supplementary Table S6 , Supplemental digital content 6, http:// links.lww.com/MR/A55), none of which remained significant after the adjustment for multiple testing. Five of them, HSP90B1, ACVR1C, LEF1, FGF17, and VEGFA, were also significant in TCGA. The sign of the association was the same in all genes except one, FGF17, which was negative in the discovery set (correlation coefficient = − 0.39, P = 0.03) and positive in the validation (TCGA) set (correlation coefficient = 0.34, P = 0.03). LEF1 remained significant in the validation set after adjustment for multiple testing. No finding remained significant in the joint analysis.
Tumor mitotic rate
We identified 76 genes nominally associated with TMR.
The genes are shown in Supplementary Table S7 (Supplemental digital content 7, http://links.lww.com/MR/A56).
Six genes nominally significant in the pilot InterMEL study, MSH6, RAD51, CCNA2, SUV39H2, CDC6, and MSH2, were also nominally significant in TCGA. For all genes, the sign of association was the same in both data sets. CCNA2 and female  female  female  male  female  female  female  female  female  female  male  male  male  male  male  male  male  male  male  male  female  female  female  male  female  female  female  male  male  male  male  male   ABL1  CACNA1D  H3F3C  GLI3  PRKCA  BDNF  KDM5C  KDM6A  CACNB4  FGFR3  LAMB4  WNT3  WNT16  COL11A1  GAS1  PPP2R2B  SETBP1  MAP2K6  FIGF  RAD50  SMO  PITX2  ATM  SOS2  IL12RB2 UBE2T remained significant in the joint analysis after the adjustment for multiple testing.
Clinical stage
We coded clinical stages starting from IIA, IIB, IIC, IIIA, IIIB, IIIC, and IV as consecutive integers and looked at the correlation with expression of each gene. We have identified 13 genes nominally associated with stage (Supplementary  Table S8 , Supplemental digital content 8, http://links.lww. com/MR/A57). None of them remained significant after adjustment for multiple testing or was detected even as nominally significant in the TCGA sample.
Survival analysis
A total of 31 nominally significant genes were identified (Supplementary Table S9 , Supplemental digital content 9, http://links.lww.com/MR/A58). None of the genes were significant after adjustment for multiple testing. We did not use the TCGA SKCM data set for validation, because survival data were available for only two of 53 primary melanoma samples.
We found that the average expression of 14 genes in metastatic melanomas predicts survival (Fig. 2) . Those 14 genes were identified on the basis of analysis of primary melanomas (comparison of LN-positive vs. LN-negative cases).
Overall correlation of differentially expressed genes between pilot InterMEL and TCGA samples
The sample size in this analysis is relatively small, which leads to insufficient statistical power to detect small associations. In contrast, the large number of genes (and statistical tests) may lead to false positives. To deal with these issues, we used TCGA samples for independent validation. True positives are expected to have similar patterns of differential expression in both samples, that is, true positives are expected to be consistent between the discovery (pilot InterMEL) and the validation (TCGA SKCM) samples, while false positives will be uncorrelated. As a measure of differential expression of the gene, we used t-statistics for categorical variables and correlation coefficient for quantitative traits. We looked at parallelism of differential expression in discovery and validation samples. For example, we used t-statistics for gender differences for each of the 753 genes. We estimated correlation of t-statistics between the pilot InterMEL and the TCGA samples to estimate the overall consistency between the discovery and the validation samples ( Table 2 ). The strongest overall consistency between pilot InterMEL and TCGA samples was detected for TILs, followed by Breslow's thickness, LN status, ulceration status, and clinical stage. No significant associations were detected for TMR or sex. The TCGA sample size was very small for TMR, only being reported for five patients, which may explain why there was no association identified.
Least absolute shrinkage and selection operator analysis Table 3 shows genes with β≠0 in LASSO analysis. The number of significant genes varies from two for clinical stage to 20 for TILs. Survival curves for high versus low expression of the 14 genes differentially expressed in primary melanomas. A median of the score based on the average, normalized, log-transformed expression of 14 genes was used to stratify cases into high and low expressed ones. DFS, disease-free survival; GSE, gene set enrichment; HR, hazard ratio; OS, overall survival; TCGA, The Cancer Genome Atlas. Gene expression in primary melanoma Gorlov et al. 385
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Gene set enrichment analysis
The results of the GSEA are shown in Table 4 . The G2M_CHECKPOINT was the most frequently associated pathway; it was significantly associated with LN status, ulceration status, Breslow thickness, TMR, and clinical stage. TMR is the phenotype with the largest number (six) of associated functional categories. Table 5 shows genes contributing to the enrichment of gene sets listed in Table 4 .
Discussion
Our goal was to demonstrate an approach for investigating associations between gene expression in primary melanomas and patient characteristics that are relevant for melanoma progression and survival and may be used to develop a reliable molecular prognostic signature on the basis of gene expression.
We identified two genes in the InterMEL and TCGA samples that were statistically significantly associated with sex after the adjustment for multiple testing: KDM5C and KDM6A. Both genes are located on the X chromosome in relative proximity to each other (Xp11.3 and Xp11.22, respectively). The gene expression levels for these two genes are about twice as high in female patients, as compared with male patients, suggesting that Table 3 Genes that remained significant in the least absolute shrinkage and selection operator models Outcomes  Significant genes   Sex  KDM5C, KDM6A, BDNF  TILs  BID, CDC25C, ETV4, FANCB, FLNA, GNG7, HPGD, ID2, LEF1, MAP2K1, MCM2, MLF1, NRAS, PIK3R1, PIK3R3, PPP2R1A,  SFRP4, STMN1, SYK, TGFBR2  Breslow thickness  CACNB2, EGF, EPO, H3F3A, ITGB4, LIF, MAD2L2, MAP3K12, MCM6, MMP9, PTEN, SHC1, TLX1, TNFRSF10C, WNT7A  Tumor mitotic rate  AKT1, CACNB2, CASP7, CCNA2, COL2A1, H3F3A, HELLS, ITGA7, MCM6, MMP9 , PTEN, SHC1, UBE2T Lymph node status ALKBH2, ARID1B, BCOR, CALML6, CCND2, EPO, FZD9, GZMB, IL2RA, MET, NFKB1, NPM2, PBRM1, POLE2, PTPN11, TNC, VDR Ulceration AKT1, DSC1, HPGD, IL23A, NR4A3, SETD2, SHC4, SOCS3, WHSC1 Clinical stage ABL1, LTA4H
TILs, tumor-infiltrating lymphocytes. 
We used GSEA Hallmark pathways for this analysis. LN, lymph node; TILs, tumor-infiltrating lymphocytes; TMR, tumor mitotic rate. Table 5 Genes contributing to the enrichment of functional categories listed in Table 4 Gene sets Differentially expressed genes E2F_TARGETS  MYC, MSH2, RAD50, CDK4, BRCA2, RAD21, MCM4, WEE1, PRKDC, HELLS, RFC3, CDC25A, MCM3,  MCM7, CDKN2A, SRSF2, STMN1, CHEK2, BRCA1, MCM2, KPNA2  EPITHELIAL_MESENCHYMAL_TRANSITION  INHBA, IL15, TNC, FLNA, ITGA2, COMP, JUN, THBS1, PDGFRB, DKK1, VEGFA, FZD8, COL1A1,  VEGFC, IGFBP3, COL1A2, ITGB3, COL3A1, ID2, GJA1, SFRP4, COL5A1, FN1, FAS, COL5A2, GAS1,  COL11A1, BDNF  ESTROGEN_RESPONSE_LATE  BCL2, SFN, FOS, IDH2, JAK1, CACNA2D2, FGFR3, KLF4, CXCL14, TIAM1, LAMC2, JAK2, ID2  G2M_CHECKPOINT  MYC, MSH2, RAD50, CDK4, BRCA2, RAD21, MCM4, WEE1, PRKDC, HELLS, RFC3, CDC25A, MCM3,  MCM7, CDKN2A, SRSF2, STMN1, CHEK2, BRCA1, MCM2, KPNA2  IL6_JAK_STAT3_SIGNALING  STAT1, STAT3, GRB2, CD14, CRLF2, PIM1, CSF2, PIK3R5, JUN, TNF, CSF3R, PLA2G2A, IL3RA, IL1R2,  IL1R1, TLR2, MAP3K8, IL2RA, IL7, SOCS1, ACVR1B  INFLAMMATORY_RESPONSE  CCR7, PIK3R5, IL7R, IL1B, IL2RB, IL1A, IRAK2, IL8, RASGRP1, OSM, RELA, NFKBIA, CSF3R  INTERFERON_GAMMA_RESPONSE  PIM1, NFKB1, PLA2G4A, ITGB7, IL2RB, NFKBIA, CD40, JAK2, TNFSF10, IL15, STAT4, IL7,  CASP8, SOCS1  KRAS_SIGNALING_DN  WNT16, EGF, FGF22, TLX1, CALML5, TGFB2, CNTFR, FGFR3  MYC_TARGETS_V1  MYC, CDK2, CDK4, MCM4, U2AF1, MCM7, SRSF2, MCM2, KPNA2, MCM5, HDAC2, PCNA, RFC4  TNFA_SIGNALING_VIA_NFKB  NR4A3, SOCS3, TNC, BTG1, EFNA1, FOSL1, LIF, IL6, VEGFA, DUSP5, BIRC3, IL1A, LAMB3, INHBA,  NFKBIA, IL1B, CLCF1, RELA, NR4A1 incomplete inactivation of the X chromosome might contribute to the observed differences in expression levels. KDM5C (lysine demethylase 5C) is involved in the regulation of transcription and chromatin remodeling, and KDM6A (lysine demethylase 6A) catalyzes the demethylation of trimethylated/dimethylated histone H3. Although the relevance of these genes in relation to sex differences and melanoma survival is not clear, KDM5C mutations have been reported in association with recurrence and survival in renal cell carcinoma [30] . KDM6A plays a role in transcriptional regulation in cancer including bladder and pancreatic cancer [31, 32] .
We have identified five genes significantly associated with quantity of lymphocytes in primary tumors assessed as TILs. Only two of them, IL1R2 and PPL, have evidence supporting an association with immune response. The expression level of LEF1 was positively associated with Breslow thickness. LEF1 plays an important role in the regulation of growth and differentiation of melanocytes and melanoma [33] . It may influence melanoma development through Wnt/β-catenin signaling pathway in melanoma epithelial-to-mesenchymal-like transition [34] . Two genes found to be significantly associated with LN status, PIK3CG and IL2RA, have been shown to play important roles in melanoma development through regulation of tumor cell adhesion and invasion and immune response [35] .
The association of CCNA2 with TMR also remained significant after the adjustment for multiple testing; the expression of this gene positively correlates with mitotic rate. CCNA2 controls both the G1/S and the G2/M transition in the cell cycle. It was identified as a prognostic marker for melanoma survival [36] . CCNA2 has been shown to induce autophagy in melanoma cells [37] . Ubiquitin conjugating enzyme E2 T (UBE2T) gene was also significantly associated with TMR in the InterMEL sample after adjustment for multiple testing. The expression level of the gene in the tumor has shown to positively correlate with cell proliferation and tumor progression in different types of cancer [38, 39] .
Surprisingly, we did not detect genes whose expression level in primary melanomas was significantly associated with clinical stage. One of the possible explanations may be that the selected genes do not show gradual changes in expression but rather may have stage-specific differences that we cannot detect because of the limited sample size (the number of patients for any specific stage is between one and six in our samples). In addition, stage at diagnosis does not necessarily relate to tumor aggressiveness, which we would not necessarily hypothesize as related to tumor gene expression.
The results of the LASSO regression are consistent with the results of univariate analysis in that, if the number of associated genes was high for a given phenotype, the number of significant genes was also high in the LASSO analysis. However, because of a relatively small sample size, we consider the results of the multivariate regression analyses as preliminary.
The most significant gene detected in survival analysis was RAD50. We found that low expression of RAD50 in primary melanoma is associated with a better survival. This finding is consistent with reported studies wherein low expression level (or mutational alterations) of RAD50 was associated with a better survival in breast [40] , colorectal [41] , and gastric [42] cancers [40] [41] [42] . Together with our findings, the results suggest that the association between somatic alterations of RAD50 may be of a pan-cancer nature and likely reflect modifications of basic biological functions, for example, genomic instability [43] .
In GSEA, we have identified a number of biological functions that remained significant after correction for multiple testing. In the majority of cases, identified functions were logically associated with phenotypes. Examples include 'interferon gamma response' associated with TILs, 'G2M checkpoint' associated with TMR, and 'TNFA signaling via NFKB' associated with ulceration status. Surprising findings include 'epithelial mesenchymal transition' associated with sex and 'estrogen response' associated with TILs. These findings need to be validated on a larger data set to be generated by the InterMEL project.
Our study had a number of strengths, including analysis of gene expression with respect to many clinically relevant factors in a modestly sized cohort of samples, and, importantly, many of our findings were further substantiated using publically available TCGA data. Further, our proof of principle study shows the feasibility of extracting high-quality RNA from FFPE samples of SKCM, many of which were over a decade old, with 90% of the samples being of sufficient quality for large-scale expression analyses. However, our study is not without limitations. We used targeted analysis of preselected genes, and this approach may have omitted some important signals from genes that were not included in the analysis. The reason we used a candidate-genome approach instead of a whole-genome approach is because of the inherent limitations of archived primary melanomas. Namely, the amount and the quality of the extracted RNA, and the presence of melanin in some cases, preclude us from using other platforms. In contrast, the amount and quality of the tissue-derived RNA presented no limitations with the Nanostring platform. In addition, we only used samples from patients with stage II and higher melanoma, and thus our findings may not be relevant to stage I melanoma patients.
Conclusion
We show that the expression of several genes in InterMEL and SKCM is associated with clinically relevant tumor features as well as patient characteristics.
Findings from this study might suggest targets for future drug development to treat melanoma. Future studies will be needed to validate these, as well as assess their association with other variables, such as patient survival.
